Susquehanna International Group
BBIO icon

Susquehanna International Group’s BridgeBio Pharma BBIO Stock Holding History

Susquehanna International Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.7M Buy
653,224
+254,281
+64% +$17.8M ﹤0.01% 1526
2026
Q1 		$29.6M Sell
398,943
-88,433
-18% -$6.41M ﹤0.01% 1755
2025
Q4 		$37.3M Buy
487,376
+145,510
+43% +$9.55M ﹤0.01% 1616
2025
Q3 		$17.8M Sell
341,866
-292,707
-46% -$14.3M ﹤0.01% 2327
2025
Q2 		$27.4M Sell
634,573
-105,131
-14% -$3.82M ﹤0.01% 1683
2025
Q1 		$25.6M Sell
739,704
-484,578
-40% -$16.3M ﹤0.01% 1522
2024
Q4 		$33.6M Buy
1,224,282
+509,125
+71% +$13.2M 0.01% 1425
2024
Q3 		$18.2M Buy
715,157
+38,508
+6% +$1.01M ﹤0.01% 1924
2024
Q2 		$17.1M Buy
676,649
+618,296
+1,060% +$16.9M ﹤0.01% 1892
2024
Q1 		$1.8M Sell
58,353
-43,962
-43% -$1.5M ﹤0.01% 5579
2023
Q4 		$4.13M Sell
102,315
-305,338
-75% -$9.17M ﹤0.01% 4043
2023
Q3 		$10.7M Buy
407,653
+14,292
+4% +$406K ﹤0.01% 2464
2023
Q2 		$6.77M Sell
393,361
-131,947
-25% -$1.99M ﹤0.01% 3049
2023
Q1 		$8.71M Buy
525,308
+447,691
+577% +$5.22M ﹤0.01% 2640
2022
Q4 		$591K Sell
77,617
-180,426
-70% -$1.73M ﹤0.01% 7411
2022
Q3 		$2.56M Buy
258,043
+208,650
+422% +$2.17M ﹤0.01% 4409
2022
Q2 		$448K Sell
49,393
-123,304
-71% -$1.03M ﹤0.01% 8548
2022
Q1 		$1.75M Sell
172,697
-233,634
-57% -$2.4M ﹤0.01% 5776
2021
Q4 		$6.78M Buy
406,331
+355,718
+703% +$15M ﹤0.01% 3252
2021
Q3 		$2.37M Buy
50,613
+30,957
+157% +$1.66M ﹤0.01% 5478
2021
Q2 		$1.2M Buy
19,656
+13,387
+214% +$765K ﹤0.01% 7257
2021
Q1 		$386K Sell
6,269
-11,780
-65% -$771K ﹤0.01% 10059
2020
Q4 		$1.28M Sell
18,049
-2,255
-11% -$109K ﹤0.01% 6090
2020
Q3 		$761K Sell
20,304
-7,971
-28% -$251K ﹤0.01% 6779
2020
Q2 		$922K Sell
28,275
-16,930
-37% -$516K ﹤0.01% 6104
2020
Q1 		$1.31M Buy
+45,205
New +$1.4M ﹤0.01% 4760
2019
Q4 		– Sell
-10,078
Closed -$216K – 9704
2019
Q3 		$216K Buy
+10,078
New +$279K ﹤0.01% 8941

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Susquehanna International Group's BBIO Position: Q2 2026 in Review

Susquehanna International Group increased its BridgeBio Pharma (BBIO) stake by 64% in Q2 2026, buying an estimated $17.8M and bringing the position to 653,224 shares worth $48.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1526.

Susquehanna International Group first reported a position in BBIO in Q3 2019 and has held it in 27 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Susquehanna International Group held 653,224 shares of BridgeBio Pharma worth $48.7M as of Q2 2026.
  • Susquehanna International Group bought 254,281 BridgeBio Pharma shares in Q2 2026, an estimated $17.8M.
  • BridgeBio Pharma made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #1526 holding.
  • Susquehanna International Group first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 27 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.